Clinical Trial Update: Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is investigating whether the kappa opioid receptor mediates ketamine's ability to reduce suicidal thoughts in individuals with major de…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Ketamine (ketamine)

Snippet

Sponsor: New York State Psychiatric Institute | Conditions: Major Depressive Disorder (MDD) | Phase 4 | Status: NOT_YET_RECRUITING